© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
Hyperbaric oxygen therapy: its use in medical emergencies and its development in Hong Kong
Joe KS Leung, MHM (UNSW), FHKAM (Emergency Medicine)1; Rex PK Lam, MPH, FHKAM (Emergency Medicine)2
1 Accident and Emergency Department, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong
2 Emergency Medicine Unit, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong
Corresponding author: Dr Joe KS Leung (email@example.com)
Hyperbaric oxygen therapy is widely accepted as life-saving treatment for decompression illness. Yet its use in acute carbon monoxide poisoning has remained controversial because of inconsistent findings in clinical trials. Hyperbaric oxygen therapy has an adjunctive role in managing gas gangrene, necrotising soft-tissue infection, and crush injury, as supported by case series. Several cases have been reported in the literature detailing the use of hyperbaric oxygen therapy in patients with severe anaemia in whom blood transfusion is not possible. Today, use of hyperbaric oxygen therapy in Hong Kong is limited by low awareness among physicians and patients, a lack of service access, and inadequate hospital and critical care support for the existing non-hospital facility. The recent introduction of a hospital-based facility is expected to benefit more patients for whom hyperbaric oxygen therapy is appropriate. This article reviews the mechanistic basis of and emerging scientific evidence to support the use of hyperbaric oxygen therapy in a number of acute medical emergencies, as well as the past and future development of hyperbaric oxygen therapy in Hong Kong.
Hyperbaric oxygen therapy (HBOT) is not a new treatment modality. Medical use of alterations in ambient pressure can be traced back to 1662, when Henshaw built the first hyperbaric chamber (Domicilium), a century before the discovery of oxygen.1 The beneficial effects of increased pressure as therapy for decompression illness (DCI) became evident more than 100 years ago, leading subsequently to the discovery of a synergy between pressure and high oxygen levels that provides the physical and biological basis of what is now known as ‘hyperbaric oxygen therapy’. This therapy is now used in a wide range of medical conditions and hyperbaric medicine has emerged as a clinical discipline in many countries. Today, the use of HBOT in Hong Kong is still limited because of low awareness among physicians and patients, and lack of access to an HBOT facility, especially in the hospital setting. In this article, we review the mechanistic basis of and evidence supporting the use of HBOT in five selected medical emergencies, as well as the past and future development of HBOT service in Hong Kong.
Clinical use of hyperbaric oxygen therapy
Defined by the Undersea and Hyperbaric Medical Society (UHMS), HBOT is “an intervention in which an individual breathes near 100% oxygen intermittently while inside a hyperbaric chamber that is pressurised to greater than sea level pressure (1 atmosphere absolute, 1 ATA)”.2 The pressure must exceed 1.4 ATA for clinical purposes and its application must be systemic to the patient’s body—that is, topical application is not considered HBOT. Hyperbaric chambers are classified according to occupancy. Monoplace chambers are designed for a single person and generally pressurised with 100% oxygen. Multiplace chambers are intended for concurrent use by more than one patient and are pressurised with air, with oxygen given via a face-mask, hood tent, or endotracheal tube.
Whereas pressure per se has some therapeutic effect in bubble-related diseases, the biological essence of HBOT is extreme hyperoxia, enabled via increased pressure. Under pressure, the physical behaviour of gases is governed by gas laws; those that are fundamental to understanding HBOT are summarised in Table 1.3 Of note, HBOT has complex biological effects that extend beyond increasing the amount of dissolved oxygen. Over the years, different additional mechanisms and applications have been reported in the literature.
Table 1. Gas laws and their implications for hyperbaric oxygen therapy3
At present, the UHMS approves 14 clinical indications for HBOT (Box).2 Different treatment protocols (known as treatment tables), consisting of different combinations of pressure and durations of oxygen and air breathing, have been devised for different conditions. The incidence of adverse effects is reported to be between 5 and 50 per 1000 HBOT exposures, depending on the indication, clinical setting, treatment protocol, and patient’s conditon.4 The adverse effects of and contra-indications to HBOT are summarised in Tables 2 and 3, respectively. Because of limited space, this article focuses on five acute medical conditions encountered in the emergency setting: DCI, carbon monoxide (CO) poisoning, acute infections, acute crush injuries, and severe anaemia. Readers are advised to refer to the relevant literature for clinical indications not covered in this article.
Box. Indications for hyperbaric oxygen therapy approved by the Undersea and Hyperbaric Medical Society2
Decompression illness is caused by an acute reduction in ambient pressure leading to formation of intravascular or extravascular gas bubbles. Gas embolism and decompression sickness (DCS) are the two major forms.
Gas embolism occurs when gas enters the arterial (arterial gas embolism [AGE]) or venous (venous gas embolism [VGE]) circulation. Diving and iatrogenic gas embolism are the two main causes.5 Diving embolism is precipitated by rapid ascent, breath-holding, or the presence of pre-existing lung pathology. Overexpansion of the lung during ascent causes barotrauma, alveolar or small airway rupture, and air entry into the pulmonary veins followed by air transit to the arterial circulation. Iatrogenic gas embolism can occur as a complication of a variety of invasive medical procedures, including central line placement, cardiopulmonary bypass, laparoscopic surgery, and a range of open surgical procedures.6 In general, VGE is relatively better tolerated because gas in the venous system is filtered by the pulmonary vessels. Venous gas, however, can migrate to the arterial system when there is right-to-left shunting (eg, through a patent foramen ovale) or pulmonary filtration overload (large amount of bubbles), causing ‘paradoxical embolism’.7
In AGE, the gas bubbles can occlude any end artery, directly inducing distal tissue ischaemia. However, most AGE pathology probably accrues from damage to the endothelium, triggering a cascade of haemostatic and inflammatory responses, endothelial leak and vasogenic oedema, and ischaemia-reperfusion injury.5 6 Clinical manifestations, usually sudden in onset (or for divers, within a few minutes of surfacing), depend on the location of the gas embolus and the quantity of gas. Of note, AGE can result in severe morbidity or even death if it involves coronary or cerebral arteries. Coronary artery emboli can lead to myocardial ischaemia, cardiac failure, dysrhythmia, or even cardiac arrest. Cerebral AGE can present as a stroke with focal neurological deficits, loss of consciousness, seizure, or even coma.
Decompression sickness occurs when the rate of ambient pressure reduction exceeds that of inert gas (mainly nitrogen) washout from tissue. When a diver ascends following a period of time underwater, the partial pressure of dissolved inert gas in capillaries and tissues is greater than the ambient pressure (Henry’s Law and Dalton’s Law) and off-gassing occurs. If supersaturation results, bubbles form in venous blood and/or tissues. The reported threshold dive depth for DCS is about 6 m but problems arise only after very prolonged times at such shallow pressures.8 Such sickness is very uncommon after diving to depths of less than 10 m. The risk is also affected by multiple factors such as immersion (vs dry hyperbaric chamber exposure), exercise, and temperature. In DCS, extravascular (autochthonous) bubbles cause mechanical distortion of tissues, leading to pain or dysfunction, depending on the tissue involved; intravascular bubbles cause a VGE that can arterialise.9 Decompression sickness has a wide range of potential manifestations that begin minutes to days after surfacing, including constitutional symptoms such as malaise; joint pain that commonly involves the knees and characteristically improves on local tissue pressure; mild neurological symptoms, such as numbness or paraesthesias; and skin rash (livedo reticularis). Severe cases can present with cardiopulmonary collapse, loss of consciousness, incomplete or complete spinal cord paresis, or severe vestibular dysfunction.
Diagnosis of DCI is primarily based on clinical findings. Clinicians should be aware of the possibility of AGE or DCS when patients present with compatible symptoms and a history of recent diving. The possibility of AGE should be considered in any case of sudden-onset clinical deterioration after high-risk medical procedures. Differentiation between AGE and DCS in divers may be difficult but is not necessary when selecting patients for recompression therapy.9
Supportive treatment is the mainstay of pre-hospital and initial emergency treatment for DCI. High-flow oxygen is used to correct hypoxia and to create a diffusion gradient from tissue to alveolar gas for the egress of nitrogen and other gases from the bubbles. For both AGE and DCS, recompression with HBOT is widely accepted as the definitive and potentially life-saving treatment despite a lack of randomised controlled trials (RCTs) in humans. Its use is supported by more than 100 years of clinical experience, rigorous mechanistic and outcomes-based research in animal models and human volunteers. The initial response to therapeutic pressurisation is in accordance with Boyle’s Law—at 2.8 ATA pressure; bubble volume is immediately reduced by two-thirds.10 Hyperoxia corrects tissue hypoxia and, by minimising blood nitrogen, maximises the diffusion gradient from the embolised gas to circulating plasma, thus optimising off-gassing. Furthermore, HBOT has anti-oedema and anti-inflammatory effects in acute injury, in particular inhibiting neutrophil adhesion to blood vessels, thus reducing reperfusion injury. The therapy is associated with significant improvement in the majority of patients with AGE.9 11 12 Of note, HBOT should be initiated early once the patient is stabilised—the UHMS recommends 100% oxygen at 2.8 ATA, with treatment repeated until symptoms completely resolve or there is no further improvement, typically after no more than five to ten treatments.2 13
Acute carbon monoxide poisoning
Hyperbaric oxygen therapy has been used in a variety of acute poisoning settings, including those caused by CO, methylene chloride, hydrogen sulphide, and carbon tetrachloride; gas embolism resulting from hydrogen peroxide ingestion; and methaemoglobinaemia.14 This article focuses on CO poisoning, as it remains a major cause of non-medicinal poisoning death15 and often results in persistent or delayed neurological sequelae.16
The pathophysiology of CO poisoning is complex and readers are referred to excellent reviews by Weaver16 and Roderique et al17 for details. In brief, CO causes tissue hypoxia by forming carboxyhaemoglobin (COHb) and shifting the oxyhaemoglobin dissociation curve to the left. It also binds to various haem proteins, impairs mitochondrial function, causes release of nitric oxide and free radicals, and triggers inflammation through a myriad of mechanisms independent of hypoxia.16 17 18 19
Oxygen therapy is the standard treatment. It works by reversing hypoxia, competing with CO for haemoglobin binding, and shortening the half-life of COHb (from 320 min in room air to about 70 min with 100% oxygen at 1 ATA); HBOT further reduces its half-life to 20 min (100% at 2.5 ATA), and increases the amount of dissolved oxygen in the plasma.20 Recent studies have shown that HBOT also restores mitochondrial function,21 reduces brain lipid peroxidation,22 and inhibits the CO-induced inflammatory response by inhibiting β2 integrin–mediated neutrophil adhesion to brain microvasculature and by inhibiting lymphocyte sensitisation to myelin basic protein.23 24 25
Hyperbaric oxygen therapy was first used for CO poisoning in 196026 but has remained controversial owing to the conflicting results of RCTs of its effect on delayed neurological sequelae. These are summarised in Table 4.27 28 29 30 31 32 A Cochrane review in 2011 that involved six RCTs and 1361 participants showed that HBOT does not have a significant benefit in a pooled random-effects meta-analysis (odds ratio for neurological deficits, 0.78; 95% confidence interval, 0.54-1.12). The reviewers cautioned that the “significant methodologic and statistical heterogeneity” and “design or analysis flaws” of the included trials warrant cautious interpretation of the results.33 The American College of Emergency Physicians, on the basis of a systematic literature review, stated that “It remains unclear whether [hyperbaric oxygen therapy] is superior to normobaric oxygen therapy for improving long-term neurocognitive outcomes” in CO-poisoned patients.34 Nonetheless, a recent population-based retrospective cohort study in Taiwan involving 7278 patients showed that HBOT was associated with reduced mortality in patients with CO poisoning after adjusting for covariates, especially in those who were younger than 20 years and those with acute respiratory failure.35 These findings add weight to the argument in support of HBOT use in CO poisoning.
Table 4. Summary of randomised controlled trials comparing hyperbaric oxygen and normobaric oxygen for carbon monoxide poisoning
Yet, the threshold for HBOT use for CO poisoning varies across different centres36 and uncertainties exist regarding the optimal chamber pressure, number and frequency of sessions, and time window after CO poisoning. In particular, pregnant women pose special challenges as they are at high risk of adverse effects from both CO and HBOT, although information is lacking because they are excluded from most prospective trials. In view of the devastating fetal outcomes of maternal CO poisoning, such as stillbirth and damage to and anatomic malformation of the fetal central nervous system, COHb thresholds for HBOT are often set lower for pregnant patients (COHb, 15%-20%) and HBOT is often considered indicated when there is evidence of fetal distress.14 Clinical experience in Russia supports the contention that HBOT is safe during pregnancy,37 38 but its benefit in averting CO-related adverse fetal outcomes is unclear.14 In CO-poisoned children, indications for HBOT are similar to those for adults, although they have not been evaluated systematically.39 Studies have reported that HBOT has been used safely in paediatric patients39 40 but there are special paediatric considerations. Readers are referred to the review by Liebelt41 for further information.
Before more convincing evidence is available, clinicians are advised to weigh the benefits, risks, and costs of HBOT carefully on a case-by-case basis when making a decision about HBOT for CO-poisoned patients. It is commonly suggested that HBOT should be reserved for (1) situations where there are indicators of higher-severity CO poisoning, such as loss of consciousness, abnormal neurological signs, cardiovascular dysfunction, or severe acidosis; (2) patients older than 35 years; (3) prolonged exposure (eg, >24 hours) or high COHb level (eg, ≥25%16). The most recent UHMS guidelines nevertheless recommend that HBOT be considered for all cases of acute symptomatic CO poisoning, given the lack of predictive factors for poor long-term outcomes or for which patients might receive the greatest benefit from HBOT.2
Hyperbaric oxygen therapy is directly bactericidal and/or bacteriostatic to anaerobes, facultative anaerobes, and many aerobes as a result of bacterial intolerance of the excess oxygen radicals induced by HBOT. The therapy improves tissue oxygenation, maximises oxygen-dependent phagocytic function, reduces tissue oedema, and potentiates uptake and/or action of various antimicrobial drugs, including the aminoglycosides, fluoroquinolones, and vancomycin.42 The therapy has been used as an adjunct in a variety of life-threatening bacterial infections—in particular, those with associated tissue necrosis such as gas gangrene, necrotising fasciitis, and other necrotising soft tissue infections (NSTIs).
Gas gangrene is a rare but fulminant infection that is most commonly caused by Clostridium perfringens and germinates in devitalised and hypoxic tissue. The lethal α-toxin produced by the organism causes rapidly progressing liquefactive myonecrosis. Hyperbaric oxygen therapy is bactericidal to C perfringens43 and inhibits toxin production.44 Experimental studies and case series support the use of HBOT as an adjunct to surgery and antibiotic therapy for gas gangrene.42 Three sessions of HBOT at 3 ATA for 90 min should be given in the first 24 h, followed by twice-daily treatments for the next 2 to 5 days, until infection control is achieved.2 45
Other forms of NSTI, often polymicrobial, are often both life- and limb-threatening. Early HBOT adjunctive to surgery and antibiotic therapy has been associated with improved survival and limb salvage,46 47 48 although several other small case series have suggested no benefit.49 50 In a large case series that involved 1583 NSTI cases in 14 US centres with their own facilities, HBOT was associated with increased survival and fewer complications in the sickest group of patients.51 In heterogeneous, high-acuity, and relatively uncommon conditions like NSTI, where there is no RCT support for any particular therapeutic strategy and none is likely, clinicians must base their decision-making on evidence from observational studies supported by interpretation of known pathophysiology and therapeutic mechanisms, as well as from any relevant animal data.52 Hyperbaric oxygen therapy is mechanistically attractive and supported by what appear to be good outcomes from experienced centres that routinely use HBOT. It should be considered in patients with serious NSTI, provided that referral for such treatment does not defer aggressive surgery and antibiotic therapy. The recommended hyperbaric oxygen protocol is 2.0 to 2.5 ATA for 90 min twice daily until the infection is controlled.2 45
In addition to necrotising bacterial infections, there are reports supporting HBOT use in treating intracranial abscess, actinomycosis, and mucormycosis in immunocompromised patients.45 Diabetic foot infections, refractory osteomyelitis, and certain implant infections are also important indications for HBOT, but they are outside the scope of this article.
Acute crush injuries and severe anaemia
Crush injury is a spectrum of injury ranging from minor contusions to limb-threatening damage. The energy of trauma can cause damage to multiple tissues. Damage to the microvasculature causes self-perpetuating fluid transudation, tissue oedema, interstitial bleeding, stasis, tissue hypoperfusion, and hypoxia. Compartment syndrome occurs when the tissue fluid pressure within a skeletal muscle compartment exceeds the capillary perfusion pressure to the muscle and nerves in the compartment. Hyperbaric oxygen therapy works by interrupting the oedema-ischaemia vicious cycle. It induces inflow vasoconstriction and reduces tissue oedema, thus improving microcirculatory blood flow. It also improves tissue oxygen delivery, which is essential in multiple oxygen-dependent host responses to trauma and infection, mitigates reperfusion injury, and enhances wound healing.53
The use of HBOT in crush injury is supported by one small RCT that showed the effectiveness of HBOT in improving wound healing and reducing repetitive surgery, especially in older patients with Gustillo grade III soft-tissue injuries.54 A systematic review of nine studies involving 150 patients with crush injury showed that HBOT is likely to be beneficial if administered early.55 A larger and more rigorous RCT on open tibial fractures with severe associated soft-tissue injury will be published in the near future.56 For compartment syndrome, no RCT has been published, but the use of HBOT is supported by animal studies and small case series.53 The treatment regimen varies depending on the type of injury, ranging from 2 to 2.4 ATA for 90 min for two or more treatments a day to 120 min for a single daily treatment.2 53
There are situations in which blood transfusion is not possible for major blood loss owing to religious or practical reasons. Hyperbaric oxygen therapy can compensate for haemoglobin deficiency by increasing the amount of dissolved oxygen in the plasma to a level sufficient to maintain tissue oxygen delivery, even in the total absence of red blood cells. Prolonged, continuous HBOT cannot, however, be used to maintain life for the multiple days necessary for autologous replacement of red blood cells, as pulmonary oxygen toxicity becomes an intolerable and eventually fatal side-effect. Literature reports suggest the potential to use intermittent HBOT as a short-term measure to relieve hypoxic symptoms in patients with otherwise intolerably low haemoglobin levels while waiting for red blood cells to regenerate or in patients with limited compatible donor options while waiting for compatible blood products to be delivered.57 58 59 60
Past and future development of a hyperbaric oxygen therapy service in Hong Kong
The year 1994 witnessed a major development of HBOT in Hong Kong. Previously, HBOT was provided by the British Royal Navy at the HMS Tamar base and was confined to diving-related conditions. The Recompression Treatment Centre was commissioned in 1994 by the Hong Kong Government on Stonecutters Island and has become the major HBOT provider since then. The facility, comprising a three-compartment multiplace chamber, is managed by the Fire Services Department under the medical supervision of the Occupational Medicine Division of the Department of Health. Nonetheless, it is primarily used during diver training by the Fire Services Department. Medical use is mainly for emergency DCI treatment and CO poisoning cases referred from public hospitals, and many elective sessions are devoted to radionecrosis treatment.61 Its remote location and lack of back-up critical care facilities, however, render it unsuitable for critically ill patients because of the risks inherent in patient transportation. Furthermore, lack of properly trained local hyperbaric physicians and expertise as well as a lack of human resources and training opportunities hinder the development of HBOT in Hong Kong. Low awareness among physicians and patients makes the referral for this treatment even less frequent. Although HBOT is also provided by a private centre in Hong Kong, patient access remains very limited.
One of the most important questions to address in developing an HBOT service in Hong Kong is its service need in our locality. Current data from the Recompression Treatment Centre (200-300 sessions for 20-30 patients per year) offer limited insight since access to the service is limited. To assess the need accurately, it would be necessary to estimate the number of patients in Hong Kong in whom HBOT is indicated and the proportion of persons with each condition who might benefit from HBOT. Doing so would depend on multiple factors including considering alternative treatments available for each condition, cost and financing, and doctor and patient beliefs and acceptance. Unfortunately, treatment thresholds for each of the many possible indications are not widely agreed on, or even researched, and the appropriate criteria for referral vary widely in practice, between nations and even between locations within nations. It must also be acknowledged that the referral rates for HBOT are strongly influenced by its availability, integration into the health care system, and the reputation of individual facilities and their clinical leaders.
One way of estimating the need for HBOT service is to study the data at health system level on the number of chambers and activity level in other countries. Internationally, Australia offers a good example. There, the eight major HBOT facilities are evenly distributed, with one major government hospital-based facility in each of its seven states and territory capital cities, excluding Canberra, plus one in Townsville, the major infrastructure city serving North Queensland and the Great Barrier Reef tourism zone. In addition, there are four active private facilities and several more being planned. Each of the major hospital-based facilities operates a large multiplace chamber, most commonly of ‘triple lock’ (three compartment) design, that can be configured to provide critical care as well as ambulatory care. Most facilities also operate one or more monoplace chambers to provide flexibility and allow efficient staff utilisation.
All government hospital-based facilities in Australia are integrated with major academic tertiary hospitals. The indications and thresholds for HBOT in Australia are conservative by international standards and can therefore be seen as a good guide to what would be a reasonable aim for Hong Kong. With 12 facilities serving a population of approximately 24 million in Australia, each facility provides 2000 to 5000 treatment sessions every year. While emergency patients receive one to several treatment sessions, non-emergency patients typically receive 20 to 40 treatment sessions spanning 4 to 8 weeks. The workload is in the range of 2000 to 5000 HBOT sessions for 100 to 350 patients per centre per year, with two to three scheduled 2-h sessions per day and six to ten non-emergency patients per scheduled session.
Hong Kong has a population of 7 million and there exists a need for at least one HBOT hospital-based facility, especially for critically ill patients. In 2010, a task force was set up in the Hospital Authority to review the development of HBOT. Approval was finally given in 2014 to establish the first hospital-based HBOT centre at the Pamela Youde Nethersole Eastern Hospital. This new centre will be managed by the Accident and Emergency Department in collaboration with the Intensive Care Unit. The facility has been designed to be close to the resuscitation room of the Accident and Emergency Department and the service will be operationally supported by the Intensive Care Unit. With the establishment of the first public hospital-based HBOT, it is expected that it will be possible to offer additional treatment options for conditions where HBOT is indicated. For instance, DCI and CO-poisoned patients can be referred to the Pamela Youde Nethersole Eastern Hospital for screening for suitability for HBOT and management. Life-threatening infections, such as gas gangrene and NSTI, and limb-threatening crush injuries can be managed with HBOT as an adjunct to conventional therapy. It is also expected that HBOT will be made available to many patients with chronic conditions such as non-healing diabetic wounds, compromised skin flaps and grafts, and radionecrosis in the out-patient setting. The hospital-based HBOT centre will also provide more opportunity for local training and research.
With the opening of the first hospital-based HBOT centre in Hong Kong in 2018, management of conditions such as DCI, CO poisoning, NSTI, and acute crush injuries may change dramatically, in terms of treatment choices as well as the logistics of patient transfer between hospitals. Involvement of emergency physicians as facilitators, modulators, and coordinators in this treatment will also widen the scope of HBOT application and strengthen collaboration with other disciplines.
The authors have no conflicts of interest to disclose.
1. Clarke D. History of hyperbaric therapy. In: Neuman TS, Thom SR, editors. Physiology and Medicine of Hyperbaric Oxygen. Philadelphia: Saunders; 2008: 3-23.
2. Weaver LK, editor. Hyperbaric Oxygen Therapy Indications. 13th ed. North Palm Beach, FL: Best Publishing Company; 2014.
3. Hardy K. The physics of hyperbaric oxygen therapy. In: Neuman TS, Thom SR, editors. Physiology and medicine of hyperbaric oxygen. Philadelphia: Saunders; 2008: 57-64.
4. Mathieu D. Contraindications to hyperbaric oxygen therapy. In: Neuman TS, Thom SR, editors. Physiology and medicine of hyperbaric oxygen. Philadelphia: Saunders; 2008: 587-98.
5. Fukaya E, Hopf HW. HBO and gas embolism. Neurol Res 2007;29:142-5. Crossref
6. Muth CM, Shank ES. Gas embolism. N Engl J Med 2000;342:476-82. Crossref
7. Gronert GA, Messick JM Jr, Cucchiara RF, Michenfelder JD. Paradoxical air embolism from a patent foramen ovale. Anesthesiology 1979;50:548-9. Crossref
8. Van Liew HD, Flynn ET. Direct ascent from air and N2-O2 saturation dives in humans: DCS risk and evidence of a threshold. Undersea Hyperb Med 2005;32:409-19.
9. Vann RD, Butler FK, Mitchell SJ, Moon RE. Decompression illness. Lancet 2011;377:153-64. Crossref
10. Branger AB, Lambertsen CJ, Eckmann DM. Cerebral gas embolism absorption during hyperbaric therapy: theory. J Appl Physiol (1985) 2001;90:593-600. Crossref
11. Trytko BE, Bennett MH. Arterial gas embolism: a review of cases at Prince of Wales Hospital, Sydney, 1996 to 2006. Anaesth Intensive Care 2008;36:60-4.
12. Moon RE, Gorman DF. Treatment of the decompression disorders. In: Brubakk AO, Neuman TS, editors. Bennett and Elliot’s Physiology and Medicine of Diving. 5th ed. London: WB. Saunders Company Ltd; 2003: 600-50.
13. Moon RE, Sheffield PJ. Guidelines for treatment of decompression illness. Aviat Space Environ Med 1997;68:234-43.
14. Thom SR. Antidote in depth: hyperbaric oxygen. In: Hoffman RS, Howland MA, Lewin NA, Nelson LS, Goldfrank LR, editors. Goldfrank’s Toxicologic Emergencies. 10th ed. New York: McGraw Hill Education; 2015: 1594-601.
15. Sircar K, Clower J, Shin MK, Bailey C, King M, Yip F. Carbon monoxide poisoning deaths in the United States, 1999 to 2012. Am J Emerg Med 2015;33:1140-5. Crossref
16. Weaver LK. Clinical practice. Carbon monoxide poisoning. N Engl J Med 2009;360:1217-25. Crossref
17. Roderique JD, Josef CS, Feldman MJ, Spiess BD. A modern literature review of carbon monoxide poisoning theories, therapies, and potential targets for therapy advancement. Toxicology 2015;334:45-58.
18. Hampson NB, Piantadosi CA, Thom SR, Weaver LK. Practice recommendations in the diagnosis, management, and prevention of carbon monoxide poisoning. Am J Resp Crit Care 2012;186:1095-101. Crossref
19. Thom SR, Fisher D, Zhang J, Bhopale VM, Cameron B, Buerk DG. Neuronal nitric oxide synthase and N-methyl-D-aspartate neurons in experimental carbon monoxide poisoning. Toxicol Appl Pharmacol 2004;194:280-95.
20. Peterson JE, Stewart RD. Absorption and elimination of carbon monoxide by inactive young men. Arch Environ Health 1970;21:165-71. Crossref
21. Brown SD, Piantadosi CA. Recovery of energy metabolism in rat brain after carbon monoxide hypoxia. J Clin Invest 1992;89:666-72. Crossref
22. Thom SR. Antagonism of carbon monoxide-mediated brain lipid peroxidation by hyperbaric oxygen. Toxicol Appl Pharmacol 1990;105:340-4. Crossref
23. Thom SR. Functional inhibition of leukocyte β2 integrins by hyperbaric oxygen in carbon monoxide-mediated brain injury in rats. Toxicol Appl Pharmacol 1993;123:248-56. Crossref
24. Thom SR, Mendiguren I, Hardy K, et al. Inhibition of human neutrophil β2-integrin-dependent adherence by hyperbaric O2. Am J Physiol 1997;272(3 Pt 1):C770-7. Crossref
25. Thom SR, Bhopale VM, Fisher D. Hyperbaric oxygen reduces delayed immune-mediated neuropathology in experimental carbon monoxide toxicity. Toxicol Appl Pharmacol 2006;213:152-9. Crossref
26. Smith G, Sharp GR. Treatment of carbon-monoxide poisoning with oxygen under pressure. Lancet 1960;276:905-6. Crossref
27. Raphael JC, Elkharrat D, Jars-Guincestre MC, et al. Trial of normobaric and hyperbaric oxygen for acute carbon monoxide intoxication. Lancet 1989;2:414-9. Crossref
28. Thom SR, Taber RL, Mediguren II, Clark JM, Hardy KR, Fisher AB. Delayed neuropsychologic sequelae after carbon monoxide poisoning: prevention by treatment with hyperbaric oxygen. Ann Emerg Med 1995;25:474-80. Crossref
29. Mathieu D, Wattel F, Mathieu-Nolf M, et al. Randomized prospective study comparing the effect of HBO versus 12 hours NBO in non comatose CO poisoned patients: results of the interim analysis [abstract]. Undersea Hyperb Med 1996;23:7-8.
30. Scheinkestel CD, Bailey M, Myles PS, et al. Hyperbaric or normobaric oxygen for acute carbon monoxide poisoning: a randomised controlled clinical trial. Med J Aust 1999;170:203-10.
31. Weaver LK, Hopkins RO, Chan KJ, et al. Hyperbaric oxygen for acute carbon monoxide poisoning. N Engl J Med 2002;347:1057-67. Crossref
32. Annane D, Chadda K, Gajdos P, Jars-Guincestre MC, Chevret S, Raphael JC. Hyperbaric oxygen for acute domestic carbon monoxide poisoning: two randomized controlled trials. Intensive Care Med 2011;37:486-92. Crossref
33. Buckley NA, Juurlink DN, Isbister G, Bennett MH, Lavonas EJ. Hyperbaric oxygen for carbon monoxide poisoning. Cochrane Database Syst Rev 2011;(4):CD002041. Crossref
34. American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on Carbon Monoxide Poisoning; Wolf SJ, Maloney GE, Shih RD, Shy BD, Brown MD. Clinical policy: Critical issues in the evaluation and management of adult patients presenting to the emergency department with acute carbon monoxide poisoning. Ann Emerg Med 2017;69:98-107.e6. Crossref
35. Huang CC, Ho CH, Chen YC, et al. Hyperbaric oxygen therapy is associated with lower short- and long-term mortality in patients with carbon monoxide poisoning. Chest 2017;152:943-53. Crossref
36. Mutluoglu M, Metin S, Ibrahim Arziman, Uzun G, Yildiz S. The use of hyperbaric oxygen therapy for carbon monoxide poisoning in Europe. Undersea Hyperb Med 2016;43:49-56.
37. Van Hoesen KB, Camporesi EM, Moon RE, Hage ML, Piantadosi CA. Should hyperbaric oxygen be used to treat the pregnant patient for acute carbon monoxide poisoning? A case report and literature review. JAMA 1989;261:1039-43. Crossref
38. Elkharrat D, Raphael JC, Korach JM, et al. Acute carbon monoxide intoxication and hyperbaric oxygen in pregnancy. Intensive Care Med 1991;17:289-92. Crossref
39. Yarar C, Yahut A, Akin A, Yildiz B, Dinleyici EC. Analysis of the features of acute carbon monoxide poisoning and hyperbaric oxygen therapy in children. Turk J Pediatr 2008;50:235-41.
40. Waisman D, Shupak A, Weisz G, Melamed Y. Hyperbaric oxygen therapy in the pediatric patient: the experience of the Israel Naval Medical Institute. Pediatrics 1998;102:E53. Crossref
41. Liebelt EL. Hyperbaric oxygen therapy in childhood carbon monoxide poisoning. Curr Opin Pediatr 1999;11:259-64. Crossref
42. Cimşit M, Uzun G, Yildiz S. Hyperbaric oxygen therapy as an anti-infective agent. Expert Rev Anti Infect Ther 2009;7:1015-26. Crossref
43. Kaye D. Effect of hyperbaric oxygen on Clostridia in vitro and in vivo. Proc Soc Exp Biol Med 1967;124:360-6. Crossref
44. Unnika V. Inhibition of toxin production in Clostridium perfringens in vitro by hyperbaric oxygen. Antonie Van Leeuwenhoek 1965;31:181-6. Crossref
45. Jacoby I. Clostridial myositis, necrotizing fasciitis, and zygomycotic infections. In: Neuman TS, Thom SR, editors. Physiology and medicine of hyperbaric oxygen therapy. Philadelphia: Saunders Elsevier; 2008: 397-418.
46. Wilkinson D, Doolette D. Hyperbaric oxygen treatment and survival from necrotizing soft tissue infection. Arch Surg 2004;139:1339-45. Crossref
47. Escobar SJ, Slade JB Jr, Hunt TK, Cianci P. Adjuvant hyperbaric oxygen therapy (HBO2) for treatment of necrotizing fasciitis reduces mortality and amputation rate. Undersea Hyperb Med 2006;32:437-43.
48. Devaney B, Frawley G, Frawley L, Pilcher DV. Necrotizing soft tissue infections: the effect of hyperbaric oxygen on mortality. Anaesth Intensive Care 2015;43:685-92.
49. Shaw JJ, Psoinos C, Emhoff TA, Shah SA, Santry HP. Not just full of hot air: hyperbaric oxygen therapy increases survival in cases of necrotizing soft tissue infections. Surg Infect (Larchmt) 2014;15:328-35. Crossref
50. Brown DR, Davis NL, Lepawsky M, Cunningham J, Kortbeek J. A multicenter review of the treatment of major truncal necrotizing infections with and without hyperbaric oxygen therapy. Am J Surg 1994;167:485-9. Crossref
51. Shupak A, Shoshani O, Goldenberg I, Barzilai A, Moskuna R, Bursztein S. Necrotizing fasciitis: an indication for hyperbaric oxygenation therapy? Surgery 1995;118:873-8. Crossref
52. Levett D, Bennett MH, Millar I. Adjunctive hyperbaric oxygen for necrotizing fasciitis. Cochrane Database Syst Rev 2015;(1):CD007937. Crossref
53. Strauss MB. The effect of hyperbaric oxygen in crush injuries and skeletal muscle-compartment syndromes. Undersea Hyperb Med 2012;39:847-55.
54. Bouachour G, Cronier P, Gouello JP, Toulemonde JL, Talha A, Alquier P. Hyperbaric oxygen therapy in the management of crush injuries: a randomized double-blind placebo-controlled clinical trial. J Trauma 1996;41:333-9. Crossref
55. Garcis-Covarrubias L, McSwain NE Jr, Van Meter K, Bell RM. Adjuvant hyperbaric oxygen therapy in the management of crush injury and traumatic ischemia: an evidence-based approach. Am Surg 2005;71:144-51.
56. Millar IL, McGinnes RA, Williamson O, et al. Hyperbaric Oxygen in Lower Limb Trauma (HOLLT); protocol for a randomised controlled trial. BMJ Open 2015;5:e008381. Crossref
57. Hart GB. Exceptional blood loss anemia. Treatment with hyperbaric oxygen. JAMA 1974;228:1028-9. Crossref
58. McLoughlin PL, Cope TM, Harrison JC. Hyperbaric oxygen therapy in the management of severe acute anaemia in a Jehovah’s witness. Anaesthesia 1999;54:891-5. Crossref
59. Greensmith JE. Hyperbaric oxygen reverses organ dysfunction in severe anemia. Anesthesiology 2000;93:1149-52. Crossref
60. Graffeo C, Dishong W. Severe blood loss anemia in a Jehovah’s Witness treated with adjunctive hyperbaric oxygen therapy. Am J Emerg Med 2013;31:756.e3-4. Crossref
61. Ramaswami RA, Lo WK. Use of hyperbaric oxygen therapy in Hong Kong. Hong Kong Med J 2000;6:108-12.